Vir Biotechnology Inc [VIR] stock is trading at $4.61, up 2.22%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VIR shares have gain 1.32% over the last week, with a monthly amount drifted -22.78%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
Vir Biotechnology Inc [VIR] stock has fluctuated between $4.32 and $14.45 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $4.61 at the most recent close of the market. An investor can expect a potential return of 333.84% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 20.86M for the trailing twelve months, which represents a drop of -94.62%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -30.81%, Pretax Profit Margin comes in at -29.51%, and Net Profit Margin reading is -29.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.47 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Vir Biotechnology Inc’s Current Ratio is 6.79. Also, the Quick Ratio is 6.79, while the Cash Ratio stands at 1.99. Considering the valuation of this stock, the price to sales ratio is 30.55, the price to book ratio is 0.61.
Transactions by insiders
Recent insider trading involved De Backer Marianne, Chief Executive Officer, that happened on Apr 03 ’25 when 79712.0 shares were sold. Officer and Director, Marianne De Backer completed a deal on Apr 03 ’25 to buy 79712.0 shares. Meanwhile, EVP and General Counsel de Verneuil Vanina sold 7373.0 shares on Feb 26 ’25.
